Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FLT3 exon 14 ins TP53 wild-type |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins TP53 wild-type | acute myeloid leukemia | sensitive | Milademetan + Quizartinib | Phase I | Actionable | In a Phase I trial, combination of Vanflyta (quizartinib) and Milademetan led to a complete response with incomplete hematologic recovery (CRi) in 40% (4/10) and stable disease (SD) in 30% of patients with TP53 wild-type acute myeloid leukemia harboring a FLT3-ITD, with a CRi of 50% (3/6) at the recommended dose; and the combination inhibited Flt3 signaling and synergistically induced apoptosis in culture and decreased leukemia growth in a cell line xenograft model (PMID: 40327322; NCT03552029). | 40327322 |